Profound Medical talks Tulsa use by Texas Prostate

Executive Summary

• Texas Prostate and Dallas Medical Center have launched a new program to perform Profound Medical Corp.'s Tulsa procedures for prostate cancer and benign prostatic hyperplasia (BPH) without surgery.
• The collaboration expands access to the Tulsa procedure, which recently received Medicare coverage in January 2025, allowing treatment in hospital outpatient, ambulatory surgical center, and private office settings.
• The Tulsa-Pro system is an AI-powered, MRI-guided robotic system that ablates targeted prostate tissue with precision, offering a non-invasive alternative to traditional surgery with no procedural blood loss and same-day discharge.

Key Details

• Partnership Structure: Texas Prostate will perform Tulsa procedures exclusively at Dallas Medical Center's state-of-the-art MRI suite.
• Target Conditions: The program treats men with prostate cancer and benign prostatic hyperplasia (BPH).
• Regulatory Context: Medicare coverage for the Tulsa procedure was granted in January 2025, broadening access to hospital outpatient, ambulatory surgical center, and private office/non-facility settings.
• Technology Specifications:
  • The Tulsa-Pro system is the only artificial-intelligence-powered, MRI-guided robotic system for prostate treatment.
  • It uses robotically guided, directional ultrasound to precisely ablate targeted prostate tissue without harming surrounding structures.
  • The procedure involves real-time MR guidance, AI-enhanced planning, and closed-loop temperature feedback control.
  • Tissue is heated to 55 to 57 C to kill targeted prostate tissue.
• Clinical Benefits:
  • Incision-free and radiation-free.
  • No procedural blood loss.
  • Significantly lower risk of complications compared to surgery.
  • No hospital stay required; patients return home the same day.
  • Preserves urinary continence and sexual function.
  • Quick recovery to normal routines.
• Regulatory Approvals: Tulsa-Pro is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA.
• Additional Product Info: Profound Medical is also commercializing Sonalleve, a platform for uterine fibroids and bone metastases pain treatment, with approvals in China and FDA humanitarian device exemption for osteoid osteoma.

Notable Quotes

• Dr. James Cochran, Founder, Texas Prostate: "The Tulsa procedure is integral to our practice because it offers many men effective prostate treatment without the life-altering side effects of surgery -- such as incontinence or erectile dysfunction... Working with Dallas Medical Center allows us to do just that."
• Ruben Garza, CEO, Dallas Medical Center: "At Dallas Medical Center, we're committed to bringing advanced, compassionate care to our patients... patients can be treated with the Tulsa-Pro system in our state-of-the-art MRI suite and then return home the same day, with no procedural blood loss and a significantly lower risk of complications."
• Arun Menawat, CEO, Profound Medical Corp.: "The versatility of Tulsa enables the treatment of a wide variety of prostate disease... we are thrilled to see that this new program will provide access to a wider population of patients. Importantly, it also provides a model for private-pay urology practices and Medicare accepting hospitals nationwide seeking to expand access to the Tulsa procedure."